Regenxbio presented three-year durability data for Surabgene (lomparvovec) in non-proliferative diabetic retinopathy at the Retina Society 59th Annual Scientific Meeting in Los Angeles.
In long-term follow-up from the Phase II ALTITUDE study (data as of 17 August 2026), a single in-office suprachoroidal administration at dose level 3 (1.0×10^12 GC/eye) demonstrated a durable efficacy profile.
Sixty percent of dose level 3 participants with three-year visits (6 of 10) achieved greater than two-step improvement on the Diabetic Retinopathy Severity Scale without additional treatment and experienced no vision-threatening events.
No intraocular inflammation was observed through three years (n=17) with short-course prophylactic topical steroids.
Regenxbio said the results are consistent with earlier two- and a half-year findings and noted that dose level 3 is being evaluated in the Phase IIb/III NAAVIGATE trial.
